Prospective Grant of an Exclusive Patent License: Anti-CD56 as an Antibody-Drug Conjugate (“ADC”) or Non-ADC To Target Glioblastoma Either Alone or in Combination With Other Potential Immuno-Oncology Drugs., 53390-53391 [2020-18988]
Download as PDF
<![CDATA[
53390
Federal Register / Vol. 85, No. 168 / Friday, August 28, 2020 / Notices
and design process. Proper NEPA
documentation will be completed based
on the outcome of that review.
Dated: August 22, 2020.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes
of Health.
[FR Doc. 2020–18926 Filed 8–27–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Cell Biology
Integrated Review Group Cellular Signaling
and Regulatory Systems Study Section.
Date: September 24–25, 2020.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health
Rockledge II 6701 Rockledge Drive Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: David Balasundaram,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5189,
MSC 7840, Bethesda, MD 20892, 301–435–
1022, balasundaramd@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: August 24, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–18955 Filed 8–27–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Prospective Grant of an Exclusive
Patent License: Anti-CD56 as an
Antibody-Drug Conjugate (‘‘ADC’’) or
Non-ADC To Target Glioblastoma
Either Alone or in Combination With
Other Potential Immuno-Oncology
Drugs.
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Cancer Institute
Clinical Trials and Translational
Research Advisory Committee.
The meeting will be held as a virtual
meeting and is open to the public.
Individuals who plan to view the virtual
meeting and need special assistance or
other reasonable accommodations to
view the meeting, should notify the
Contact Person listed below in advance
of the meeting. The meeting will be
videocast and can be accessed from the
NIH Videocasting and Podcasting
website (https://videocast.nih.gov).
Name of Committee: National Cancer
Institute Clinical Trials and Translational
Research Advisory Committee.
Date: November 4, 2020.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: Strategic Discussion of NCI’s
Clinical and Translational Research
Programs.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Rockville,
MD 20850 (Virtual Meeting).
Contact Person: Sheila A. Prindiville, M.D.,
MPH Director, Coordinating Center for
Clinical Trials, National Institutes of Health,
National Cancer Institute, Coordinating
Center for Clinical Trials, 9609 Medical
Center Drive, Room 6W136, Rockville, MD
20850, 240–276–6173, prindivs@
mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
deainfo.nci.nih.gov/advisory/ctac/ctac.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: August 25, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–18986 Filed 8–27–20; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
17:16 Aug 27, 2020
Jkt 250001
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
National Institutes of Health,
Health and Human Services. (HHS).
ACTION: Notice.
AGENCY:
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patents and Patent Applications listed
in the Supplementary Information
section of this notice to Connectyx
Technologies Holdings Group
(‘‘Connectyx’’) located in Boca Raton,
FL.
SUMMARY:
Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before September 14, 2020 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: Jasmine Yang, Ph.D., Senior
Licensing and Patenting Manager at
Telephone: (240)-276–5530 or at Email:
jasmine.yang@nih.gov.
SUPPLEMENTARY INFORMATION:
DATES:
Intellectual Property
(1) U.S. Provisional Patent Application
No. 62/119,707 filed July 31, 2015.
HHS Ref No. E–221–2015–0–US–01
(2) PCT Application No. PCT/US2016/
044777 filed 07/29/2016. HHS Ref.
No. E–221–2015–0–PCT–02
(3) U.S. Patent No. 10,548,987 issued
February 02, 2020 (Patent Application
No. 15/747,620 filed January 25,
2018). HHS Ref. No. E–221–2015–0–
US–03.
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to the use
of Licensed Patent Rights for the
following: Anti-CD56 as an antibodydrug conjugate (‘‘ADC’’) to target and
treat glioblastoma either alone or in
E:\FR\FM\28AUN1.SGM
28AUN1
Federal Register / Vol. 85, No. 168 / Friday, August 28, 2020 / Notices
combination with other potential
immuno-oncology drugs.
This technology discloses the
composition of an ADC comprising a
drug conjugated to CD56-specific
monoclonal antibodies, m900 and
m906, or an antigen-binding fragment,
wherein the drug comprises a cytotoxic
agent, including but not limited to PBD,
and to methods of using the ADCs for
treating neuroblastoma, small-cell lung
cancer, multiple myeloma, acute
myeloid leukemia, NK–T lymphoma,
and neuroendocrine cancer. This notice
is made in accordance with 35 U.S.C.
209 and 37 CFR part 404. The
prospective exclusive license will be
royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: August 20, 2020.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2020–18988 Filed 8–27–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
VerDate Sep<11>2014
17:16 Aug 27, 2020
Jkt 250001
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Biological Chemistry
and Macromolecular Biophysics Integrated
Review Group; Biochemistry and Biophysics
of Membranes Study Section.
Date: September 28–29, 2020.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Nuria E. Assa-Munt, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4164,
MSC 7806, Bethesda, MD 20892, (301) 451–
1323, assamunu@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Cancer Health Disparities.
Date: September 28–29, 2020.
Time: 9:30 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ola Mae Zack Howard,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4192,
MSC 7806, Bethesda, MD 20892, (301) 451–
4467, howardz@mail.nih.gov.
Name of Committee: Cell Biology
Integrated Review Group; Nuclear and
Cytoplasmic Structure/Function and
Dynamics Study Section.
Date: September 28–29, 2020.
Time: 11:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jessica Smith, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, jessica.smith6@nih.gov.
Name of Committee: Healthcare Delivery
and Methodologies Integrated Review Group;
Health Services Organization and Delivery
Study Section.
Date: September 29–30, 2020.
Time: 8:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jacinta Bronte-Tinkew,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3164,
MSC 7770, Bethesda, MD 20892, (301) 806–
0009, brontetinkewjm@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–19–
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
53391
264: Imaging, Biomarkers and Digital
Pathomics for the Early Detection of
Premetastatic Aggressive Cancer.
Date: September 29, 2020.
Time: 9:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ileana Hancu, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5116,
Bethesda, MD 20817, (301) 402–3911,
ileana.hancu@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: August 24, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–18929 Filed 8–27–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development Initial
Review Group Health, Behavior, and Context
Subcommittee.
Date: October 19, 2020.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: NICHD/NIH, 6710B Rockledge
Drive, Bethesda, MD 20892 (Virtual/
Teleconference).
Contact Person: Kimberly L. Houston,
M.D., Scientific Review Officer, Eunice
Kennedy Shriver National Institute of Child
Health and Human Development, 6710B
E:\FR\FM\28AUN1.SGM
28AUN1
]]>Agencies
[Federal Register Volume 85, Number 168 (Friday, August 28, 2020)]
[Notices]
[Pages 53390-53391]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-18988]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Anti-CD56 as an
Antibody-Drug Conjugate (``ADC'') or Non-ADC To Target Glioblastoma
Either Alone or in Combination With Other Potential Immuno-Oncology
Drugs.
AGENCY: National Institutes of Health, Health and Human Services.
(HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute, an institute of the National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of an Exclusive Patent License to practice the
inventions embodied in the Patents and Patent Applications listed in
the Supplementary Information section of this notice to Connectyx
Technologies Holdings Group (``Connectyx'') located in Boca Raton, FL.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before September 14, 2020 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated an Exclusive Patent License
should be directed to: Jasmine Yang, Ph.D., Senior Licensing and
Patenting Manager at Telephone: (240)-276-5530 or at Email:
[email protected].
SUPPLEMENTARY INFORMATION:
Intellectual Property
(1) U.S. Provisional Patent Application No. 62/119,707 filed July 31,
2015. HHS Ref No. E-221-2015-0-US-01
(2) PCT Application No. PCT/US2016/044777 filed 07/29/2016. HHS Ref.
No. E-221-2015-0-PCT-02
(3) U.S. Patent No. 10,548,987 issued February 02, 2020 (Patent
Application No. 15/747,620 filed January 25, 2018). HHS Ref. No. E-221-
2015-0-US-03.
The patent rights in these inventions have been assigned and/or
exclusively licensed to the government of the United States of America.
The prospective exclusive license territory may be worldwide and
the field of use may be limited to the use of Licensed Patent Rights
for the following: Anti-CD56 as an antibody-drug conjugate (``ADC'') to
target and treat glioblastoma either alone or in
[[Page 53391]]
combination with other potential immuno-oncology drugs.
This technology discloses the composition of an ADC comprising a
drug conjugated to CD56-specific monoclonal antibodies, m900 and m906,
or an antigen-binding fragment, wherein the drug comprises a cytotoxic
agent, including but not limited to PBD, and to methods of using the
ADCs for treating neuroblastoma, small-cell lung cancer, multiple
myeloma, acute myeloid leukemia, NK-T lymphoma, and neuroendocrine
cancer. This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the National
Cancer Institute receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information in these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: August 20, 2020.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2020-18988 Filed 8-27-20; 8:45 am]
BILLING CODE 4140-01-P
